產(chǎn)品詳情
簡單介紹：
Anti-phospho-CYLD (Ser418)抗體產(chǎn)品質(zhì)量穩(wěn)定，實驗效果明顯，貨期快，價格優(yōu)惠，歡迎垂詢訂購！我公司長期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關(guān)試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-phospho-CYLD (Ser418)抗體用于**組化實驗,WB實驗,相應(yīng)的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-phospho-CYLD (Ser418)
Cat. Number:
Anti-phospho-CYLD (Ser418)抗體KL-3080R
Quantity size:
0.1ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Defects in CYLD are the cause of familial cylindromatosis (CYLD) also known as turban tumor syndrome or dermal eccrine cylindromatosis. CYLD is an autosomal dominant and highly tumor type-specific disorder. TheAnti-phospho-CYLD (Ser418)抗體 tumors (known as cylindromas because of their characteristic microscopic architecture) are believed to arise from or recapitulate the appearance of the eccrine or apocrine cells of the skin that secrete sweat and scent respectively. Cylindromas arise predominantly in hairy parts of the body with approximately 90% on the head and neck. The development of a confluent mass which may ulcerate or become infected has led to the designation "turban tumor syndrome". The skin tumors show differentiation in the direction of hair structures, hence the synonym trichoepithelioma. CYLD has deubiquitinating activity.
Also known as:
CDMT; cylindromatosis (turban tumor syndrome); Deubiquitinating enzyme CYLD ; EAC; HSPC057; KIAA0849; turban tumor Anti-phospho-CYLD (Ser418)抗體syndrome; Ubiquitin thiolesterase CYLD; Ubiquitin-specific processing protease CYLD; Cyld; CYLD_HUMAN; cylindromatosis 1; Ubiquitin-specific processing protease CYLD; Ubiquitin-specific-processing protease CYLD.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Pig, Cow, Horse, .
●
Immunogen: KLH conjugated Synthesised phosphopeptide derived from human CYLD around the phosphorylation site of Ser418.
●
Predicted Molecular Weight: 105kDa.
Storage:
Shipped at 4℃, Store at -20℃Anti-phospho-CYLD (Ser418)抗體 (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications.
Optimal working dilutionsAnti-phospho-CYLD (Ser418)抗體 must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutionsAnti-phospho-CYLD (Ser418)抗體 must be determined by the end user.
kl091Mu02 巨噬細胞來源趨化因子(MDC)多克隆抗體 Polyclonal Antibody to Macrophage Derived Chemokine (MDC)
kl092Mu02 巨噬細胞炎性蛋白1α(MIP1α)多克隆抗體 Polyclonal Antibody to Macrophage Inflammatory Protein 1 Alpha (MIP1a)
kl093Mu02 巨噬細胞炎性蛋白1β(MIP1β)多克隆抗體 Polyclonal Antibody to Macrophage Inflammatory Protein 1 Beta (MIP1b)
kl095Mu02 巨噬細胞炎性蛋白3α(MIP3α)多克隆抗體 Polyclonal Antibody to Macrophage Inflammatory Protein 3 Alpha (MIP3a)
kl096Mu02 巨噬細胞炎性蛋白3β(MIP3β)多克隆抗體 Polyclonal Antibody to Macrophage Inflammatory Protein 3 Beta (MIP3b)
kl097Mu02 基質(zhì)金屬蛋白酶1(MMP1)多克隆抗體 Polyclonal Antibody to Matrix Metalloproteinase 1 (MMP1)
kl098Mu02 基質(zhì)金屬蛋白酶10(MMP10)多克隆抗體 Polyclonal Antibody to Matrix Metalloproteinase 10 (MMP10)
kl100Eq01 基質(zhì)金屬蛋白酶2(MMP2)多克隆抗體 Polyclonal Antibody to Matrix Metalloproteinase 2 (MMP2)
kl100Mu02 基質(zhì)金屬蛋白酶2(MMP2)多克隆抗體 Polyclonal Antibody to Matrix Metalloproteinase 2 (MMP2)
kl100Po01 基質(zhì)金屬蛋白酶2(MMP2)多克隆抗體 Polyclonal Antibody to Matrix Metalloproteinase 2 (MMP2)
kl101Mu02 基質(zhì)金屬蛋白酶3(MMP3)多克隆抗體 Polyclonal Antibody to Matrix Metalloproteinase 3 (MMP3)
kl102Mu02 基質(zhì)金屬蛋白酶7(MMP7)多克隆抗體 Polyclonal Antibody to Matrix Metalloproteinase 7 (MMP7)
kl103Mu02 基質(zhì)金屬蛋白酶8(MMP8)多克隆抗體 Polyclonal Antibody to Matrix Metalloproteinase 8 (MMP8)
kl104Mu02 膽囊收縮素A受體(CCKAR)多克隆抗體 Polyclonal Antibody to Cholecystokinin A Receptor (CCKAR)
kl105Mu02 神經(jīng)生長因子(NGF)多克隆抗體 Polyclonal Antibody to Nerve Growth Factor (NGF)
kl106Mu02 神經(jīng)營養(yǎng)因子3(NT3)多克隆抗體 Polyclonal Antibody to Neurotrophin 3 (NT3)
kl107Mu02 神經(jīng)營養(yǎng)因子4(NT4)多克隆抗體 Polyclonal Antibody to Neurotrophin 4 (NT4)
kl108Mu02 骨保護素(OPG)多克隆抗體 Polyclonal Antibody to Osteoprotegerin (OPG)
